Acquisition (action) – Page 5

Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges

1 year ago talkbio0Tagged Acquisition (action), Capacity, Drug Industry, Drug shortages, Eli, Eli Lilly, Manufacture, Mounjaro, Nexus manufacturing, Plants, Wisconsin, Zepbound

Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition

Incyte Invests in Mast Cell Inhibitors with $750M Escient Acquisition

1 year ago talkbio0Tagged Acquisition (action), Dosage Forms, Drug Development, Escient, Fibrosis, Incyte, Inflammatory disorder, mast cell inhibitors

Incyte, Escient, mast cell inhibitors, acquisition, pharmaceutical, drug development, inflammatory diseases, cancer, fibrosis, $750 million

Incyte Expands Portfolio with $750 Million Acquisition of Escient, a Pioneer in Immune and Neuro Biotechnology

1 year ago talkbio0Tagged Acquisition (action), Biotechnology, Drug Development, Escient, expansion, G-Protein-Coupled Receptors, Immune system, Incyte, Neuroscience discipline, portfolio, targets

Incyte, Escient, biotechnology, immune system, neuroscience, acquisition, deal, $750 million, portfolio expansion, drug development, therapeutics, GPCR targets.

Sanofi’s Strategic Acquisition of Principia Bears Fruit with Rilzabrutinib’s Phase III Success

1 year ago talkbio0Tagged Acquisition (action), Biotechnology, Clinical Trials, Drug Development, Drug Industry, Investments, Phase III, Principia, Rilzabrutinib, sanofi, strategic, Success

Sanofi, Principia, acquisition, Rilzabrutinib, Phase III, clinical trial, success, strategic investment, pharmaceutical industry, biotechnology, drug development.

Vertex Acquires Alpine Immune Sciences for $4.9 Billion to Boost Immunology Trail

1 year ago talkbio0Tagged Acquisition (action), Alpine Immune Sciences, Immunology, TNFSF10 protein, human

Vertex Pharmaceuticals, Alpine Immune Sciences, $4.9 billion acquisition, Immunology trail

Genmab Acquires ProfoundBio for $1.8 Billion to Challenge AbbVie’s Elahere in ADC Market

1 year ago talkbio0Tagged AbbVie's, Acquisition (action), Antibody-Drug Conjugates, competition, Elahere, FOLR1 gene, FOLR1 protein, human, Genmab, Midphase clinical trials, ProfoundBio, Rina-S, Rinatabart sesutecan

Genmab, ProfoundBio, $1.8 billion acquisition, Antibody Drug Conjugates (ADCs), Competition with AbbVie’s Elahere, Rinatabart sesutecan (Rina-S), Folate Receptor Alpha (FRα), Midphase clinical trials